AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06498089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: This drug will be used in both arms. Patients' initial daily prednisone dose will be calculated according to their weights (0.6mg \* weight(kg), maximum 50mg/day), and then tapered gradually during the study course.
Study NCT06498089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: This drug will be used in the traditional arm. A dose of 15mg per week will be used.
Study NCT06498089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: This drug will be used in the traditional arm. A dose of 15mg per week will be used.
Study NCT06498089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: This drug will be used in the precise treatment arm. For patients in constitutional type a dose (8mg/kg weight) will be used every 2 weeks (iv drip) for 12 weeks, then a dose (8mg/kg weight) will be used every 4 weeks (iv drip). For patients in vascular inflammation type, a dose (8mg/kg weight) will be used every 4 weeks (iv drip).
Study NCT06498089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: This drug will be used in the precise treatment arm. A sustained release tablet will be used (11mg per day).
Study NCT06498089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: This drug will be used in the precise treatment arm. A dose of 40mg (ih) will used every 2 weeks.
Study NCT05117398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin administration
Description: A single-dose of intraveneuse (IV) administration of dalbavancin of 1500 mg.~In case of patients with chronic renal impairment (creatinin clairance \< 30mL/min), a single-dose of IV administration of reduced dalbavancin of 1000 mg.
Study NCT05117398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard antibiotic therapy
Description: Standard Antibiotic therapy according to national recommendations. During the study, the start of treatment is considered to be the day of inclusion/randomization (even if active antiobiotic treatment was started, less than 72 hours ago according to inclusion criteria).
Study NCT06671587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iGlarLixi (insulin glargine/lixisenatide)
Description: iGlarLixi will be supplied as a sterile aqueous solution in a pen-injector.~There will be 2 pen-injectors with different insulin glargine/lixisenatide fixed ratios which allow insulin glargine titration from 5 U/day to 40 U/day while limiting lixisenatide dose to a maximum of 20 μg/day:~- iGlarLixi must not be mixed with other insulins nor diluted.
Study NCT06671587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gla-100 (insulin glargine)
Description: Gla-100 will be supplied as a 3 mL sterile aqueous solution for SC injection in a pre-filled disposable Gla-100 SoloStar® pen containing 300 U insulin glargine (100 U/mL). Doses could be set in the range of 5 to 80 U in increments of 1 unit.
Study NCT06671938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exidavnemab
Description: The trial medication will be administered as an intravenous (IV) infusion (dose 1; dose 2)
Study NCT06671938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: The trial medication will be administered as an intravenous (IV) infusion
Study NCT06622291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Exogenous nitric oxide is directly administered to the oxygenator in the cardiopulmonary bypass circuit at a concentration of 60 ppm. Nitric oxide is also directly administered to the ventilator at a concentration of 60 ppm for 12 hours post-operation.
Study NCT06622291 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the placebo group. The standard CPB protocol involves delivering an air-gas mixture to the cardiopulmonary bypass circuit during cardiac surgery and avoiding the use of nitric oxide within 12 hours after surgery.
Study NCT06623877 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: renal shear wave elastography
Description: Renal shear wave elastography is a non-invasive ultrasound elastography technique that allows measurements of tissue stiffness. It provides real-time measurements of shear wave velocity (SWV) generated with an acoustic impulse, thereby providing quantitative information about tissue elasticity. Harder tissues have been shown to have higher SWV .~Renal shear wave elastography will be done to both groups
Study NCT06718270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cells Infusion
Description: chimeric antigen receptor T cells
Study NCT06726837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative pain - 6th hour
Description: Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 6th hour.
Study NCT06726837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative pain - 24th hour
Description: Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 24th hour.
Study NCT06726837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative pain - 48th hour
Description: Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 48th hour.
Study NCT06726837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative pain - 72nd hour
Description: Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 72nd hour.
Study NCT06726837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative pain - 7 day
Description: Patients will be given the VAS Pain Assessment Scale and asked to mark their pain levels between 0 and 10 at 7 day.
Study NCT05873335 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mixtures of nitrogen, air, and carbon dioxide
Description: Hypoxia was induced to different and stable levels of oxyhemoglobin saturation (between 70-100%) by having subjects breathe mixtures of nitrogen, air, and carbon dioxide controlled by the study physician by adjusting gas flows with valves according to breath-by-breath estimates of oxygen saturation calculated from end-tidal PO2 and PCO2 displayed on a screen using LabVIEW 2015
Study NCT06720077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: It will be applied for the experimental group only. Before starting the first treatment session, the participants will be instructed briefly about the nature of the treatment to gain their confidence and cooperation. Each participant in this group will be asked to lie in supine position and the acupressure will be applied by using the therapist's fingers on the following acupoints (san jio 6/ spleen 15/ stomach 25/ joining vally  intestine 4) 1 minute for each point with 3 repetitions on both sides (about 30 minutes as total time), 3 times per week for 6 weeks.
Study NCT06720077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercises
Description: A modified exercise will be used to achieve normal diaphragmatic breathing while the woman is lying on her back, with one hand placed on her abdomen and the other on her thorax. She will then be instructed to breathe in deeply, slowly, and gradually for 4 seconds, hold the air for 2 seconds, and exhale slowly through pursed lips for 6 seconds. Three series of ten repetitions will be completed with rest in between; the woman will be advised to rest longer if she feels dizzy or lightheaded. The patient will ensure the exercise is performed successfully if the hand placed on the abdomen shows greater mobility compared to minimal or no mobility of the hand on the thorax. From that point, the series of repetitions will begin.
Study NCT06720077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic breathing exercises
Description: A modified exercise will be used to achieve normal diaphragmatic breathing while the woman is lying on her back, with one hand placed on her abdomen and the other on her thorax. She will then be instructed to breathe in deeply, slowly, and gradually for 4 seconds, hold the air for 2 seconds, and exhale slowly through pursed lips for 6 seconds. Three series of ten repetitions will be completed with rest in between; the woman will be advised to rest longer if she feels dizzy or lightheaded. The patient will ensure the exercise is performed successfully if the hand placed on the abdomen shows greater mobility compared to minimal or no mobility of the hand on the thorax. From that point, the series of repetitions will begin.
Study NCT06720077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General bowel care advise
Description: All women in both groups will receive bowel care advice, including encouraging fiber intake (20-35 g/day) from sources like whole grains, fruits, vegetables, and legumes, with a focus on soluble fiber. They will be advised to limit meat, dairy, and low-fiber foods and avoid caffeine-containing products like chocolate and coffee. Adequate hydration (1.5-2.0 L/day) with water or juices will be recommended, along with daily exercise, such as 20-30 minutes of walking. Proper toilet posture will be emphasized, including sitting with knees higher than hips (using a stool if needed), leaning forward, placing elbows on knees, relaxing, and maintaining a straight spine.
Study NCT06720077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General bowel care advise
Description: All women in both groups will receive bowel care advice, including encouraging fiber intake (20-35 g/day) from sources like whole grains, fruits, vegetables, and legumes, with a focus on soluble fiber. They will be advised to limit meat, dairy, and low-fiber foods and avoid caffeine-containing products like chocolate and coffee. Adequate hydration (1.5-2.0 L/day) with water or juices will be recommended, along with daily exercise, such as 20-30 minutes of walking. Proper toilet posture will be emphasized, including sitting with knees higher than hips (using a stool if needed), leaning forward, placing elbows on knees, relaxing, and maintaining a straight spine.
Study NCT06730516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost (Xalatan)
Description: latanoprost 0.005
Study NCT06730516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2 %
Description: Brimonidine0.2
Study NCT06731738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteric acid
Description: A gadolinium-based contrast agent (authorised auxiliary medicinal product (AMP)) will be injected i.v. at a dose of 0.2 mmol Gd/kg bw and T1 mapping and ECV measurement will be done.
Study NCT06731738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mangafodipir trisodium injection
Description: Mangafodipir trisodium injection (IMP) will be administered i.v. at a dose of 5 µmol/kg bw and T1 mapping, Saturation Recovery T1 weighted imaging for measurement of the uptake rate, and T2 mapping, will be done.
Study NCT06730763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (TDCS) is a non-invasive, painless brain stimulation treatment that uses direct electrical currents to stimulate specific parts of the brain.
Study NCT06730763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: selected traditional physical therapy program for improve balance and decrease risk of falling
Study NCT06730763 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: selected traditional physical therapy program for improve balance and decrease risk of falling
Study NCT06230302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey postbiotics derived from kefir lactic acid bacteria
Description: Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics
Study NCT05248334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab Injection
Description: The Ranibizumab group was treated with one intravitreal injection of 0.5 mg/0.05 ml ranibizumab (Lucentis, Basel, Novartis) at baseline. While additional panretinal photocoagulation was performed if there was sufficient space and view to fill in the previously untreated areas, if needed. Repeated injections will be given after 4 weeks when the clearing of VH was incomplete (for a maximum of two injections).~If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed.
Study NCT05248334 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV
Description: Vitrectomy to remove vitreous hemorrhage and take additional panretinal photocoagulation. If vitreous hemorrhage was not absorbed/vitreous hemorrhage aggravation/proliferation membrane formation/tractive retinal detachment after 4 weeks of observation, the treatment was considered failed and PPV was performed.
Study NCT04251728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated mechanical peripheral stimulation
Description: Automated mechanical pressure reaching the pain threshold in four specific points at the foots soles
Study NCT04251728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The exercise program will be conducted for 12 weeks lasting 1 hour each session. Sessions will be held in groups and each session will comprise 4 steps: 1) Warm-up (5 min): patients will perform stretching of the main muscle groups of upper limbs, lower limbs and trunk; 2) Aerobic exercise (30 min): patients will perform continuous aerobic exercise consisting of walk on flat ground and ramps; 3) Resistance exercise training (20 min): volunteers will perform resistance exercises (2 sets x 15 repetitions) for upper and lower limbs, and trunk working the following muscle groups: shoulder flexors, extensors and abductors; elbow flexors and extensors; trunk extensors and flexors; knee flexors and extensors; and dorsiflexors and plantar flexors; 4) Cool-down (5 min): Stretching of the main muscle groups worked during the sessions and relaxation.
Study NCT04251728 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical Exercise
Description: The exercise program will be conducted for 12 weeks lasting 1 hour each session. Sessions will be held in groups and each session will comprise 4 steps: 1) Warm-up (5 min): patients will perform stretching of the main muscle groups of upper limbs, lower limbs and trunk; 2) Aerobic exercise (30 min): patients will perform continuous aerobic exercise consisting of walk on flat ground and ramps; 3) Resistance exercise training (20 min): volunteers will perform resistance exercises (2 sets x 15 repetitions) for upper and lower limbs, and trunk working the following muscle groups: shoulder flexors, extensors and abductors; elbow flexors and extensors; trunk extensors and flexors; knee flexors and extensors; and dorsiflexors and plantar flexors; 4) Cool-down (5 min): Stretching of the main muscle groups worked during the sessions and relaxation.
Study NCT04251728 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Automated mechanical pressure reaching the sensory threshold in four specific points at the foots soles
Study NCT06326684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Description: The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.
Study NCT06326684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: The pharmacodynamic effects of alcohol (0.2 and 0.4 g/kg) will be determined.
Study NCT06326684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The effects of placebo will be determined.
Study NCT06326684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: The effects of suvorexant dose 1 will be determined.
Study NCT06326684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: The effects of suvorexant dose 2 will be determined.
Study NCT05721677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate based topical skin adhesive
Description: Tissue adhesive on CVL exit-site
Study NCT05615636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given by IV (vein)
Study NCT05615636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Given by IV (vein)
Study NCT05615636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given by IV (vein)
Study NCT05615636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by PO
Study NCT06230302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.
Study NCT06210451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile water-based gel
Description: Insertion of the speculum during ET will be performed using 5 gr of water-based, sterile gel
Study NCT06174974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The education was designed to cover the environmental stressors of the intensive care unit and the practices performed to reduce these stressors. The education content was created according to the Activities of Daily Living (ADL) Theory based on the institution's cardiovascular surgical intensive care unit protocols (Cardiovascular surgical intensive care unit visitor entry-exit rules information form) and the literature (included at the end of the presentation). Expert (intensive care nurses, ward nurses, cardiovascular surgeons and academic nurses) opinions were obtained. Patient-friendly and simple language was used to ensure that the content of the information presentation was acceptable and interesting.
Study NCT04935801 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: LD vehicle-GNP
Description: Two intradermal injections in the upper arm spaced 21 days apart
Study NCT04935801 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LD PepGNP-Dengue
Description: Two intradermal injections in the upper arm spaced 21 days apart
Study NCT04935801 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: HD vehicle-GNP
Description: Two intradermal injections in the upper arm spaced 21 days apart
Study NCT04935801 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD PepGNP-Dengue
Description: Two intradermal injections in the upper arm spaced 21 days apart
Study NCT06010550 — intervention group
Intervention type: RADIATION
Intervention: Magnetic resonance imaging
Description: Brain magnetic resonance imaging
Study NCT04817033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia with intraoperative dexmedetomidine sedation
Description: Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
Study NCT05922527 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined regenerative technique
Description: Periodontal regenerative technique using amnion chorion membrane combined with DFDBA in a putty form
Study NCT05922527 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement
Description: Open flap debridement
Study NCT04817033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia with intraoperative midazolam sedation
Description: Skin was disinfected and 40mg of 2% Lidocaine was given subcutaneously at lumbar vertebrae 3/4 level. 25 G spinal needle was used and after dura and arachnoidea were pierced 12.5-15 mg of 0.5% Levobupivacaine was applied.
Study NCT04817033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5 ug/kg during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
Study NCT04817033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.25 mg/kg ideal body weight during first 10 minutes after successful spinal anesthesia. Dose maintained to keep patient in moderate sedation with closed eyes and Ramsay sedation scale 4 and 5 level
Study NCT04702399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GEL GROUP
Description: Application of an anti-adhesion gel (HYALOBARRIER® GEL ENDO) in the uterine cavity
Study NCT05362695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3300
Description: A dose of IW-3300 administered rectally (as a low-volume \[20 mL\] enema).
Study NCT05362695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A dose of placebo administered rectally (as a low-volume \[20 mL\] enema).
Study NCT05328388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycomato
Description: Lycomato sof gels
Study NCT05939791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518
Description: The commercial probiotic dairy product has been provided to PALL along with physical training once a day for 8 weeks. Each serving contained 20 billion CFUs of Lacticaseibacillus paracasei subsp. Paracasei CNCMI-1518 (Lactobacillus casei CNCMI-1518). Each patient's legal representative was advised to follow a normal diet when preparing and providing food for children.